When we see something special in oncology research,
we will go to the ends of the earth to get it done.
Craig Tendler, M.D
Vice President Janssen, Late Development and Global Medical Affairs
At Janssen we aim to fundamentally alter the way cancer is understood, diagnosed and managed. We’re committed to delivering new, transformational medicines and we’re determined to redefine the standard of care.
Our discoveries have produced new therapeutic options in prostate cancer, haematological malignancies, lung cancer and colorectal cancer. These are examples of treatments that are already helping to prolong and improve lives. But it’s just the start.
We understand that better patient outcomes depend on something more than medicine, so we’re developing a range of programs to help transform the lives of those with cancer.
Improving access to treatment and patient outcomes
We’ve partnered with a number of infusion centres to make it easier for patients to access infusion therapy. If a patient at a participating infusion centre doesn’t have private health insurance coverage for infusions, Janssen LivE will cover the costs.*
* Medication costs are not included. Not available in South Australia at the time of publication. An excess fee may apply from the patient's private health insurance.
Offering information, education and personalised care
Cancer treatment can often leave patients with more questions than answers. We can help by developing programs that work towards providing patients with personalised support, advice, education and encouragement throughout their treatment journey.
Working with key organisations to improve resources and services
Through these partnerships we support for a broad range of initiatives and help to give patients a voice.
Our partners include
- The Leukemia Foundation
- Lymphoma Australia
- The Prostate Cancer Foundation of Australia
- The Myeloma Foundation of Australia
- Rare Cancers Australia
- The Cancer Drugs Alliance and
Giving clinicians and researchers a platform to share best practice and insights
Janssen Oncology’s medical education program includes M3, with a focus on multiple myeloma, and Prospect, which is centred around advanced metastatic prostate cancer. Each program is developed by a local faculty of clinicians and researchers and created to meet current clinical needs.